Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.39 |
| ▸ | RAPGEF3 | O95398 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246728 | 0.84 | RAPGEF4 (0.40) | RAPGEF4ACLY | |
| SCHEMBL8247975 | 0.84 | FDPS (0.47) | RAPGEF4FDPSACLY | |
| SCHEMBL12764927 | 0.77 | RAPGEF4 (0.44) | RAPGEF4FDPS | |
| SCHEMBL12135857 | 0.77 | RAPGEF4 (0.44) | RAPGEF4 | |
| SCHEMBL1638576 | 0.76 | RAPGEF4 (0.53) | RAPGEF4EPAS1RAPGEF3GRM4ACLY | |
| SCHEMBL20620250 | 0.75 | RAPGEF4 (0.49) | RAPGEF4EPAS1GRM4IDH1MAOB | |
| SCHEMBL21571898 | 0.73 | EGFR (0.40) | RAPGEF4GRM4IDH1 | |
| SCHEMBL9355733 | 0.73 | MAOB (0.53) | RAPGEF4GRM4MAOBHTT | |
| SCHEMBL4185946 | 0.73 | RAPGEF4 (0.50) | RAPGEF4EPAS1GRM4ACLYMAOB | |
| SCHEMBL360242 | 0.71 | RAPGEF4 (0.48) | RAPGEF4EPAS1GRM4ACLYMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | RAPGEF4 4382/4885EPAS1 985/4885RAPGEF3 3614/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | RAPGEF4 4382/4885EPAS1 985/4885RAPGEF3 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.